We are bullish on Avid's potential take-private deal by Ampersand and GHO, predicting value creation and optimistic about ...

Fintel reports that on November 7, 2024, RBC Capital downgraded their outlook for Avid Bioservices (NasdaqCM:CDMO) from ...

On Tuesday, Avid Bioservices Inc (CDMO) stock saw a decline, ending the day at $12.23 which represents a decrease of $-0.02 or -0.16% from the prior close of $12.25. The stock opened at $12.25 and ...

Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the ...

According to Avid's CFO, as revenue increases, incremental EBITDA is expected to drop through at an ~50% rate, which is not adequately captured in the transaction price.

Avid Bioservices Inc., a Tustin-based biotech company, agreed to go private in an $850-million deal that values the company ...

Upon the completion of the merger, each share of Avid Bioservices’ common stock will be converted into the right to receive $12.50 in cash, without interest. Additionally, outstanding options ...

Avid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization, is set to be acquired by GHO Capital Partners and ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...